Ezetimibe in sirolimus-associated hyperlipidemia: To add or not to add to statins?

Annals of Transplantation

Volumn 16, Issue 3, 2011, Pages 132-134

  Niemczyk, Mariusz ^a   Paczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Ezetimibe; Hyperlipidemia; Kidney transplant; Sirolimus

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; EZETIMIBE; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80054858606     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882006     Document Type: Article

References (10)

1. Kasiske BL, de Mattos A, Flechner SM et al: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant, 2008; 8: 1384-92
2. Strony J, Hoffman R, Hanson M, Veltri E: Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clin Ther, 2008; 30: 2280-97
3. Türk TR, Voropaeva E, Kohnle M et al: Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant, 2008; 23: 369-73
4. Sharpe LJ, Brown AJ: Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Bioch Biophys Res Comm, 2008; 373: 670-74
5. Almutairi F, Peterson TC, Molinari M et al: Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl, 2009; 15: 504-8
6. Puthenparumpil JJ, Keough-Ryan T, Kiberd M et al: Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplantation Proc, 2005; 37: 1033-35
7. Buchanan C, Smith L, Corbett J et al: A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant, 2006; 6: 770-74
8. Mueller MA, Beutner F, Teupser D et al: Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis, 2008; 198: 39-48
9. Chen WQ, Zhong L, Zhang L et al: Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol, 2009; 156: 941-51
10. Andres V, Castro C, Campistol JM: Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Neprol Dial Transplant, 2006; 21(Suppl.3): iii14-17